- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03048344
A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders
Part 1 will be conducted as an open-label, non-randomized, non-placebo-controlled dose escalation study using pre-specified doses. Subjects with the following advanced hematological disorders and no available therapies, and who satisfy all inclusion/exclusion criteria will be enrolled. The purpose is to identify the recommended dose of oral ORH-2014 in subjects with advanced hematological disorders.
Part 2 will be an expansion phase conducted as a single-arm, open-label study to further evaluate the safety and tolerability of ORH-2014 at the maximum tolerated dose (MTD) or recommended dose determined from Part 1 in the fasted state. Subjects with the same disease types as in Part 1 will be enrolled. All subjects will receive oral ORH-2014, in the fasted state, at the recommended dose for an initial period of up to 12 weeks. The purpose is to evaluate the safety and tolerability of oral ORH-2014 in a population of subjects with advanced hematological disorders when administered at the recommended dose.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Weill Cornell Medical College
-
New York, New York, United States, 10065
- Memorial Sloan-Kettering Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37240
- Vanderbilt University
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Female and male subjects ≥18 years of age with one of the following:
- Relapsed or refractory acute myelocytic leukemia (AML) with nucleophosmin-1 (NPM1) mutations and no available therapies.
- Relapsed or refractory acute promyelocytic leukemia (APL), with no available therapies. Note: Prior exposure to arsenic trioxide is allowed; however, subjects who have failed arsenic trioxide within the last 12 months are not allowed.
- Relapsed or refractory myelodysplastic syndrome (MDS), International Prognostic Scoring System intermediate or high-risk, with no available therapies
- Relapsed or refractory chronic myelomonocytic leukemia (CMML), and other MDS/myeloproliferative neoplasm (MPN) overlap syndromes, with no available therapies
- Relapsed or refractory mantle cell lymphoma (MCL) with no adequate therapies.
- Negative pregnancy test at the Screening visit for women of childbearing potential and willingness to use adequate birth control
- Not willing to undergo, not a candidate for, or not having a donor for immediate (within 3 months from the Screening date) bone marrow transplantation.
Exclusion Criteria:
- Eastern Cooperative Oncology Group performance status of ≥3;
- Absolute myeloblast count ≥20,000/mm^3;
- Administration of any antineoplastic therapy within 5 half-lives of the antineoplastic therapy before the first dose of ORH-2014, with the exception of hydroxyurea that should be discontinued 1 day prior to the first dose of ORH-2014
- Presence of any remaining toxicities due to previous chemotherapy
- Participation in other clinical trials within at least 2 weeks of the first ORH-2014 dose;
- Clinical evidence of active central nervous system leukemia;
- Active and uncontrolled infection
- Major surgery within 2 weeks prior to trial entry;
- Liver function tests above the following limits at Screening: total bilirubin >1.5 x upper limit of normal (ULN) unless related to Gilbert's syndrome or hemolysis; aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2.5 x ULN; for subjects with liver involvement, AST and/or ALT >5 x ULN;
- Serum creatinine >1.5 x ULN and/or creatinine clearance or estimated glomerular filtration rate <30 mL/min
- Impaired cardiac function
- Myocardial infarction of unstable angina within 6 months prior to the planned start date of study drug.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1
Subjects will receive oral ORH-2014 at a planned starting dose of 5 mg once daily (QD) in the fasted state.
If escalation criteria are met, the administered dose will increase by 5 mg increments to a maximum of 50 mg QD.
The starting daily dose is approximately half the typical IV dose (0.15 milligram per kilogram [mg/kg]) extrapolated to a 70-kg person.
|
ORH-2014 capsule 5 mg orally with dose escalations of 5 mg intervals.
ORH-2014 capsule at recommended dose orally.
|
Experimental: Part 2
Subjects will receive a daily oral dose of ORH-2014 at the recommended dose identified in Part 1. ORH-2014 will be administered in the fasted state.
|
ORH-2014 capsule 5 mg orally with dose escalations of 5 mg intervals.
ORH-2014 capsule at recommended dose orally.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To identify the recommended dose
Time Frame: From baseline to Week 4
|
The recommended dose is determined by the number of patients who experience a dose limiting toxicity (DLT).
|
From baseline to Week 4
|
Number of Participants With Adverse Events (AE) as a Measure of Safety and Tolerability of ORH-2014 when administered at the MTD or recommended dose
Time Frame: Up to Week 28
|
To evaluate safety and tolerability the aggregate review will include but is not limited to:
|
Up to Week 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by maximum observed concentration (Cmax)
Time Frame: Baseline up to Week 24
|
Baseline up to Week 24
|
|
To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by time to maximum concentration (Tmax)
Time Frame: Baseline up to Week 24
|
Baseline up to Week 24
|
|
To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by apparent terminal elimination half-life (t1/2)
Time Frame: Baseline up to Week 24
|
Baseline up to Week 24
|
|
To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by area under the concentration-time curve from 0 to 24 hours (AUC0-24)
Time Frame: Baseline up to Week 24
|
Baseline up to Week 24
|
|
To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by area under the concentration-time curve extrapolated to infinity (AUC0-infinity)
Time Frame: Baseline up to Week 24
|
Baseline up to Week 24
|
|
To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by apparent terminal elimination rate constant (λZ)
Time Frame: Baseline up to Week 24
|
Baseline up to Week 24
|
|
To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by apparent total clearance (CL/F)
Time Frame: Baseline up to Week 24
|
Baseline up to Week 24
|
|
To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by apparent total clearance normalized by body weight (CL/F/kg)
Time Frame: Baseline up to Week 24
|
Baseline up to Week 24
|
|
To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by apparent total volume of distribution (Vz/F)
Time Frame: Baseline up to Week 24
|
Baseline up to Week 24
|
|
To determine the plasma pharmacokinetic (PK) profiles of total arsenic as measured by accumulation ratio (AR)
Time Frame: Baseline up to Week 24
|
Baseline up to Week 24
|
|
To evaluate the effect of ORH-2014 on QT-interval corrected for heart rate using Fridericia's formula (QTcF)
Time Frame: Baseline up to Week 28
|
Baseline up to Week 28
|
|
Safety Assessment during the expansion phase of the study on the effect of oral ORH-2014 on safety parameters
Time Frame: Baseline up to Week 28
|
During the expansion phase of the study, an aggregate clinical data review (ACDR) will be conducted. This review will collect data from electronic data capture, the ECG central review vendor (ERT), and other sources to include but is not limited to:
|
Baseline up to Week 28
|
The number of participants with a complete response (CR) or partial response (PR) according to International Working Group (IWG) response criteria
Time Frame: Up to Week 24
|
Bone marrow aspirates and/or biopsies will be obtained at the designated timepoints for evaluation of efficacy.
Response criteria will be according to the International Working Group.
Responders are participants who obtain complete remission (CR) or partial remission (PR), with or without cytogenetic response, and marrow complete remission.
|
Up to Week 24
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Farhad Ravandi-Kashani, MD, MD Anderson
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ORH2014-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Hematological Disorders
-
Shanghai Yuyao Biotech Co., Ltd.RecruitingAdvanced Solid Tumor | Hematological MalignancyChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingAdvanced Solid Tumors and Hematological Malignancies
-
Constellation PharmaceuticalsCompletedSolid Tumor | Advanced Malignancies | Hematological MalignancySpain, United States, Georgia
-
Novartis PharmaceuticalsCompletedAdvanced Solid and Hematological TP53wt TumorsFrance, Netherlands, Spain, Germany, Singapore, Japan, Taiwan, United States
-
Novartis PharmaceuticalsCompletedCancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological MalignanciesUnited States
-
Centre Hospitalier Universitaire de BesanconCentre Hospitalier Universitaire Saint Antoine, Paris; Centre de Lutte Contre... and other collaboratorsCompletedAdvanced Cancer | EthicsFrance
-
Hangzhou DAC Biotechnology Co., Ltd.Not yet recruitingAdvanced Solid Tumors | Hematological Malignancies
-
Antengene Discovery LimitedRecruitingAdvanced Solid Tumors | Hematological MalignanciesAustralia
-
UNC Lineberger Comprehensive Cancer CenterTerminatedHematological DisorderUnited States
-
Charite University, Berlin, GermanyUniversity of LeipzigUnknownAcute Myeloid Leukemias | Advanced Hematological Malignancies | Indication for Allogeneic Stem Cell Transplantation | no HLA-identical Donor AvailableGermany
Clinical Trials on ORH-2014
-
Sanofi Pasteur, a Sanofi CompanyCompleted
-
GlaxoSmithKlineCompleted
-
National Cancer Institute (NCI)TerminatedRefractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Solid Neoplasm | Recurrent Lung Small Cell Carcinoma | Stage IIIA Lung Small Cell Carcinoma AJCC v7 | Stage IIIB Lung Small Cell Carcinoma AJCC v7 | Stage IV Lung Small Cell... and other conditionsUnited States
-
Centre Hospitalier Universitaire de BesanconCompletedPalliative Care | Hematological Malignancy | Platelet TransfusionFrance
-
Josep Rodes-CabauiVascularCompletedCoronary Heart DiseaseSpain
-
Sanofi Pasteur, a Sanofi CompanyCompleted
-
Sam BrophyCompletedLower Back Pain | Muscle Pain | Back Pain | Acute Pain | Lower Back Pain MechanicalCanada
-
The University of The West IndiesCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Endometrial Adenocarcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast... and other conditionsUnited States